Giorgio Vittorio Scagliotti

21PUBLICATIONS
212CO-AUTHORS
Gene and molecular therapyHaematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jul 22, 2026
Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).

|Jul 12, 2025
Shifting Shapes: The Endothelial-to-Mesenchymal Transition as a Driver for Cancer Progression.

Lucia Giordanengo, Alessia Proment, Virginia Botta

|Feb 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Oct 09, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Dec 18, 2023
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.

Francesco Passiglia, Luisella Righi, Paolo Bironzo

|Nov 22, 2023
Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.

Annapaola Mariniello, Tahseen H Nasti, Daniel Y Chang

Pageof 4

Frequent Collaborators

5 joint publications

Luisella Righi

5 joint publications

Silvia Novello

5 joint publications

Fabrizio Tabbò

4 joint publications

Ferdinandos Skoulidis